论文部分内容阅读
目的:测定肾透明细胞癌中尾加压素Ⅱ(UⅡ)与其受体(UT-R)的表达量,以期探讨UⅡ与UT-R的表达在肾透明细胞癌发生中的临床意义。方法:对12例肾透明细胞癌肿瘤组织通过免疫组化检测肾透明细胞癌组织和正常肾组织UⅡ蛋白的表达,并采用逆转录-多聚酶链式反应(RT PCR)的方法测定肾透明细胞癌组织和正常肾组织UⅡmRNA和UT-RmRNA的表达量。结果:肾透明细胞癌组织和正常肾组织中有UⅡ蛋白表达。RT-PCR结果显示肾透明细胞癌中UⅡmRNA的表达明显高于正常肾组织0.92±0.09和0.62±0.06(P<0.01)。UT-R mRNA的表达明显高于正常肾组织0.28±0.01和0.16±0.03(P<0.01)。结论:肾透明细胞癌中UⅡ和UT-RmRNA高表达提示UⅡ/UT系统可能与肾透明细胞癌的发生、发展有关,UⅡ可能通过自分泌或旁分泌的方式发挥作用。
Objective: To determine the expression of urotensin Ⅱ (UⅡ) and its receptor (UT-R) in renal clear cell carcinoma in order to investigate the clinical significance of the expression of UⅡ and UT-R in renal clear cell carcinoma. Methods: The expressions of UⅡprotein in renal clear cell carcinoma tissues and normal renal tissues were detected by immunohistochemistry in 12 cases of renal clear cell carcinoma. The expression of UⅡprotein in renal clear cell carcinoma tissues and normal renal tissues was detected by reverse transcription polymerase chain reaction (RT PCR) Tissue and normal renal tissue U Ⅱ mRNA and UT-R mRNA expression levels. Results: There were UⅡprotein in renal clear cell carcinoma and normal renal tissue. RT-PCR results showed that the expression of UⅡmRNA in renal clear cell carcinoma was significantly higher than that in normal renal tissues (0.92 ± 0.09 and 0.62 ± 0.06, P <0.01). UT-R mRNA expression was significantly higher than normal renal tissue 0.28 ± 0.01 and 0.16 ± 0.03 (P <0.01). Conclusion: The high expression of UⅡ and UT-RmRNA in renal clear cell carcinoma suggest that UⅡ / UT system may be related to the occurrence and development of clear cell renal cell carcinoma. UⅡ may play its role through autocrine or paracrine processes.